Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem
- PMID: 2845057
Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem
Abstract
The distribution of the central omega 1 (benzodiazepine1; BZD1) and omega 2 (BZD2) receptor subtypes has been studied autoradiographically in monkey and human brain sections using [3H]flunitrazepam (which binds indiscriminately to omega 1 and omega 2 subtypes) and [3H]zolpidem (which recognizes selectively the omega 1 subtype). Both ligands labeled an homogeneous population of binding sites (Kd values approximately equal to 1.5 nM and approximately equal to 5 nM, respectively) whose pharmacological characteristics were similar to those of central omega (BZD) receptors. Regional displacement studies in monkey brain showed that zolpidem was a more effective displacer of [3H]flunitrazepam from omega 1-than from omega 2-enriched areas. For example, it was 73-fold more potent in the cerebellum (omega 1-enriched) than in the dentate gyrus (omega 2-enriched). Zolpidem thus selectively recognizes omega 1 sites in primate brain. The autoradiographic distribution of [3H]flunitrazepam (omega 1 + omega 2) binding sites in primate brain was highly heterogeneous. Very high densities were observed in lamina IV of the neocortex (with higher densities in the occipital than in the frontal pole), the substantia innominata and molecular layer of the dentate gyrus. Intermediate densities were found in other neocortical laminae, cerebellum (molecular layer), claustrum, globus pallidus, caudate-putamen, nucleus accumbens, dentate gyrus (granular layer) and the majority of thalamic nuclei. Structures displaying low binding densities included the substantia nigra and the subthalamic nucleus. The regional distribution pattern of [3H]zolpidem binding sites was qualitatively similar to that of [3H]flunitrazepam but the relative density of the 3H-ligands differed in several brain regions. The relative density of omega 1 and omega 2 subtypes in each particular primate brain region was evaluated by measuring 1) the ratio of [3H]zolpidem to [3H]flunitrazepam binding; 2) [3H]flunitrazepam binding in the presence and in the absence of 100 nM zolpidem. With both approaches, a preferential enrichment in omega 1 sites was observed in lamina IV of sensorimotor cortical regions and in the extrapyramidal motor system (globus pallidus, ventral thalamic complex, subthalamic nucleus, substantia nigra and cerebellum). In contrast, omega 2 sites predominated in limbic areas (e.g., the dentate gyrus, amygdala, nucleus accumbens, cingulate and parahippocampal gyri) and in the anterior thalamic nucleus and caudate nucleus.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Autoradiographic localization of [3H]zolpidem binding sites in the rat CNS: comparison with the distribution of [3H]flunitrazepam binding sites.J Neurochem. 1987 Sep;49(3):890-9. doi: 10.1111/j.1471-4159.1987.tb00977.x. J Neurochem. 1987. PMID: 3039057
-
Comparative autoradiographic distribution of central omega (benzodiazepine) modulatory site subtypes with high, intermediate and low affinity for zolpidem and alpidem.Brain Res. 1993 Feb 26;604(1-2):240-50. doi: 10.1016/0006-8993(93)90375-w. Brain Res. 1993. PMID: 8096157
-
In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype.J Pharmacol Exp Ther. 1988 Jun;245(3):1033-41. J Pharmacol Exp Ther. 1988. PMID: 2838599
-
Serotonin receptors in brain revisited.Brain Res. 2016 Aug 15;1645:46-9. doi: 10.1016/j.brainres.2015.12.042. Epub 2015 Dec 29. Brain Res. 2016. PMID: 26740406 Review.
-
Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs.Pharmacopsychiatry. 1990 May;23 Suppl 3:103-7. doi: 10.1055/s-2007-1014544. Pharmacopsychiatry. 1990. PMID: 1974068 Review.
Cited by
-
Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.Brain. 2012 Jun;135(Pt 6):1926-36. doi: 10.1093/brain/aws104. Epub 2012 May 10. Brain. 2012. PMID: 22577221 Free PMC article.
-
EEG profile of intravenous zolpidem in healthy volunteers.Psychopharmacology (Berl). 1994 Feb;114(1):138-46. doi: 10.1007/BF02245455. Psychopharmacology (Berl). 1994. PMID: 7846196 Clinical Trial.
-
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.Parkinsons Dis. 2016;2016:2531812. doi: 10.1155/2016/2531812. Epub 2016 May 17. Parkinsons Dis. 2016. PMID: 27293955 Free PMC article. Review.
-
Measurement of variation in the human cerebral GABA level by in vivo MEGA-editing proton MR spectroscopy using a clinical 3 T instrument and its dependence on brain region and the female menstrual cycle.Hum Brain Mapp. 2011 May;32(5):828-33. doi: 10.1002/hbm.21086. Hum Brain Mapp. 2011. PMID: 20645307 Free PMC article.
-
[3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study.J Autism Dev Disord. 2007 May;37(5):911-20. doi: 10.1007/s10803-006-0226-7. J Autism Dev Disord. 2007. PMID: 17019626
MeSH terms
Substances
LinkOut - more resources
Medical